Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors

Published version of a preprint

Abstract

Purpose: NC-6004, a novel cisplatin nanoparticle developed using micellar technology exhibits sustained release of cisplatin and selective distribution to tumors. Preclinical data demonstrated a favorable tolerability profile and preserved or improved antitumor activity compared with cisplatin across animal models. We evaluated the safety and tolerability of NC-6004 and gemcitabine using a Bayesian continual reassessment model (N-CRM) to determine the optimal dose. Experimental Design: Patients with advanced solid tumors received NC-6004 at 60 to 180 mg/m2 on day 1 and gemcitabine at 1,250 mg/m2 on days 1 and 8 every 3 weeks. Dose escalation of NC-6004 began with a single patient run-in until a dose-limiting toxicity occurred at 180 mg/m2. Cohorts of four patients were enrolled at doses predicted by the N-CRM. The maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity <25%. Quality of life was assessed using EORTC-QLQ-C30. Results: Among 22 patients, the most common grade III/IV hematologic adverse events were leukopenia (68%) and thrombocytopenia (59%). Of 20 pretreated patients evaluable for response, half were previously exposed to a platinum agent. The MTD was 135 mg/m2. Nine patients were treated at the MTD with median treatment duration of 15 weeks (range, 3–50). Tumor shrinkage occurred in 11 (55%), partial responses in 3 (15%), and stable disease in 14 (70%). Most patients reported stable or improved EORTC QLQ-C30 scores. Conclusions: Greater cisplatin equivalent doses were achieved with no clinically significant neuro-, oto-, or nephrotoxicity. These data demonstrate tolerability and promising activity of NC-6004 in combination with gemcitabine. Clin Cancer Res; 24(1); 43–51. ©2017 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1114

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Research works printed but not linked: 4

  1. 2011, Platinol® (cisplatin for injection, USP) [package insert]
  2. Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387
  3. 2015, NanoCarrier Investigator Brochure Edition 9.0
  4. Reitsma, 2015, We can improve trials using adaptive designs, Applied Clinical Trials, 35

Cited by

See all 124

Metadata

Authors
Subbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., Masada, A., Reitsma, D. J., & Bazhenova, L. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • 2UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
  • University of North Carolina at Chapel Hill (US)
  • University Hospitals of Cleveland (US)
  • Pharmaceutical Product Development (United States) (US)
  • NanoCarrier (Japan) (JP)
  • University of California San Diego (US)
Corresponding author
Subbiah, Vivek
Venue
Clinical Cancer Research
Published
2018-01-01
Volume
24
Issue
1
Pages
43-51
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2764334703
Cited by
118
References
28
Citations by year
2026: 11 · 2025: 16 · 2024: 11 · 2023: 7 · 2022: 25 · 2021: 16 · 2020: 12 · 2019: 13 · 2018: 6
FWCI
3.06
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Texas MD Anderson Cancer Center NIH (CA016672)
  • NCATS (UL1 TR000371)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords
gemcitabine, combination chemotherapy, advanced solid tumors, maximum tolerated dose, dose-limiting toxicity, hematologic toxicity, leukopenia, thrombocytopenia, quality of life, platinum rechallenge, anticancer activity
MeSH terms
Gemcitabine, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Organoplatinum Compounds, Polyglutamic Acid, Quality of Life, Treatment Outcome, Drug Monitoring, Drug Resistance, Neoplasm, Retreatment, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1114
The paper
Subbiah, V., Grilley-Olson, J. E., Combest, A. J., Sharma, N., Tran, R. H., Bobe, I., Osada, A., Takahashi, K., Balkissoon, J., Camp, A., Masada, A., Reitsma, D. J., & Bazhenova, L. A. (2018). Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.